Stock Scorer

PAVmed Inc. (PAVM)

PAVmed Inc. reported revenue of 33K USD for the quarter ending 30 June 2026, up 450.0% from 6K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 33K +450.0%
Gross Profit Q2 '22 · ending 30 June 2022 0 —
Operating Income Q2 '26 · ending 30 June 2026 -7M —
Net Income Q2 '26 · ending 30 June 2026 -5.4M —
Cost of Revenue Q2 '26 · ending 30 June 2026 122K +197.6%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -2.7M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -2.7M —
Shares Outstanding Q2 '26 · ending 30 June 2026 6.3M +258.9%
EPS Q4 '25 · ending 31 December 2025 -5.63 -148.0%

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 71K-21.8M401K-5.2M
20242024-12-31 3M-44.5M39.8M-33.6M
20232023-12-31 2.5M-68.8M-64.2M-52.3M
20222022-12-31 377K-91.1M-89M-72.5M
20212021-12-31 500K-54.4M-50.3M-42.1M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3033K
Q1 '262026-03-3122K
Q4 '252025-12-3152K
Q3 '252025-09-305K
Q2 '252025-06-306K
Q1 '252025-03-318K
Q4 '242024-12-3110K
Q3 '242024-09-30996K
Q2 '242024-06-30979K
Q1 '242024-03-311M
Q4 '232023-12-311M
Q3 '232023-09-30791K
Q2 '232023-06-30166K
Q1 '232023-03-31446K
Q4 '222022-12-31112K
Q3 '222022-09-3076K
Q2 '222022-06-300
Q1 '222022-03-31189K
Q4 '212021-12-31300K
Q3 '212021-09-30200K

Gross Profit Quarterly

PeriodEndingGross Profit
Q2 '222022-06-300
Q1 '222022-03-31-180K
Q4 '212021-12-31-141K
Q3 '212021-09-3056K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-7M
Q1 '262026-03-31-8M
Q4 '252025-12-31-6.8M
Q3 '252025-09-30-4.8M
Q2 '252025-06-30-4.7M
Q1 '252025-03-31-5.4M
Q4 '242024-12-31-5.2M
Q3 '242024-09-30-11.6M
Q2 '242024-06-30-13.7M
Q1 '242024-03-31-14M
Q4 '232023-12-31-16.4M
Q3 '232023-09-30-15.5M
Q2 '232023-06-30-16.5M
Q1 '232023-03-31-20.4M
Q4 '222022-12-31-24.6M
Q3 '222022-09-30-23.4M
Q2 '222022-06-30-23.5M
Q1 '222022-03-31-19.6M
Q4 '212021-12-31-19.7M
Q3 '212021-09-30-13.7M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-5.4M
Q1 '262026-03-31-60K
Q4 '252025-12-31-1.3M
Q3 '252025-09-30-5.4M
Q2 '252025-06-30-11.9M
Q1 '252025-03-3119M
Q4 '242024-12-311.4M
Q3 '242024-09-3064.4M
Q2 '242024-06-30-10.8M
Q1 '242024-03-31-15.2M
Q4 '232023-12-31-14M
Q3 '232023-09-30-17.7M
Q2 '232023-06-30-14.5M
Q1 '232023-03-31-17.9M
Q4 '222022-12-31-20.5M
Q3 '222022-09-30-26.1M
Q2 '222022-06-30-25.5M
Q1 '222022-03-31-16.9M
Q4 '212021-12-31-17.2M
Q3 '212021-09-30-12.2M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-30122K
Q1 '262026-03-3197K
Q4 '252025-12-3185K
Q3 '252025-09-3055K
Q2 '252025-06-3041K
Q1 '252025-03-3136K
Q4 '242024-12-3148K
Q3 '242024-09-301.4M
Q2 '242024-06-301.7M
Q1 '242024-03-311.7M
Q4 '232023-12-311.6M
Q3 '232023-09-301.8M
Q2 '232023-06-301.7M
Q1 '232023-03-311.3M
Q4 '222022-12-311.6M
Q3 '222022-09-301.6M
Q2 '222022-06-300
Q1 '222022-03-31369K
Q4 '212021-12-31441K
Q3 '212021-09-30144K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-2.7M
Q1 '262026-03-31-2.6M
Q4 '252025-12-31-1.6M
Q3 '252025-09-30-896K
Q2 '252025-06-30-1.2M
Q1 '252025-03-31-1.6M
Q4 '242024-12-3194K
Q3 '242024-09-30-8.9M
Q2 '242024-06-30-11.7M
Q1 '242024-03-31-13.1M
Q4 '232023-12-31-11.9M
Q3 '232023-09-30-11.1M
Q2 '232023-06-30-12.7M
Q1 '232023-03-31-16.4M
Q4 '222022-12-31-16.8M
Q3 '222022-09-30-19.3M
Q2 '222022-06-30-22.6M
Q1 '222022-03-31-12.3M
Q4 '212021-12-31-16.8M
Q3 '212021-09-30-8M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-2.7M
Q1 '262026-03-31-2.6M
Q4 '252025-12-31-1.6M
Q3 '252025-09-30-899K
Q2 '252025-06-30-1.2M
Q1 '252025-03-31-1.6M
Q4 '242024-12-3190K
Q3 '242024-09-30-8.9M
Q2 '242024-06-30-11.7M
Q1 '242024-03-31-13.2M
Q4 '232023-12-31-12.1M
Q3 '232023-09-30-11.1M
Q2 '232023-06-30-12.7M
Q1 '232023-03-31-16.4M
Q4 '222022-12-31-17.1M
Q3 '222022-09-30-19.7M
Q2 '222022-06-30-22.9M
Q1 '222022-03-31-12.8M
Q4 '212021-12-31-18.1M
Q3 '212021-09-30-8.1M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-306.3M
Q1 '262026-03-311.6M
Q3 '252025-09-3021.6M
Q2 '252025-06-30602.8K
Q1 '252025-03-311.7M
Q3 '242024-09-3044.5M
Q2 '242024-06-309.2M
Q1 '242024-03-318.7M
Q3 '232023-09-307.5M
Q2 '232023-06-307M
Q1 '232023-03-316.5M
Q3 '222022-09-3089.8M
Q2 '222022-06-3087M
Q1 '222022-03-3186.3M
Q3 '212021-09-3083.3M
Q2 '212021-06-3082.2M
Q1 '212021-03-3174M
Q3 '162016-09-3013.3M
Q2 '162016-06-3013M
Q1 '162016-03-3112.2M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q4 '252025-12-31-5.63
Q3 '252025-09-301.84
Q2 '252025-06-303.57
Q1 '252025-03-3124.46
Q4 '242024-12-3111.74
Q3 '242024-09-30-4.30
Q2 '242024-06-30-8.12
Q1 '242024-03-31-9.03
Q4 '232023-12-31-9.19
Q3 '232023-09-30-21.51
Q2 '232023-06-30-19.42
Q1 '232023-03-31-17.61
Q4 '222022-12-31-15.03
Q3 '222022-09-30-1.02
Q2 '222022-06-30-0.88
Q1 '222022-03-31-0.73
Q4 '212021-12-31-0.66
Q3 '212021-09-30-0.58
Q2 '212021-06-30-0.54
Q1 '212021-03-31-0.52